|
|---|
|
Winer A,
Denlinger CS,
Vijayvergia N,
Cohen SJ,
Astaturov I,
Dotan E,
Gallant JN,
Wang EW,
Kunkel M,
Lim B,
Harvey HA,
Sivik J,
Korzekwa K,
Ruth K,
White K,
Cooper HS,
Ross EA,
Zhou L,
El-Deiry WS. First-in-Human Phase 1b Trial of Quinacrine Plus Capecitabine in Patients With Refractory Metastatic Colorectal Cancer.
Clin Colorectal Cancer. 2021 Mar;20(1)
:e43-e52. |
|
Francescone R,
Barbosa Vendramini-Costa D,
Franco-Barraza J,
Wagner J,
Muir A,
Lau AN,
Gabitova L,
Pazina T,
Gupta S,
Luong T,
Rollins D,
Malik R,
Thapa RJ,
Restifo D,
Zhou Y,
Cai KQ,
Hensley HH,
Tan Y,
Kruger WD,
Devarajan K,
Balachandran S,
Klein-Szanto AJ,
Wang H,
El-Deiry WS,
Vander Heiden MG,
Peri S,
Campbell KS,
Astsaturov I,
Cukierman E. Netrin G1 promotes pancreatic tumorigenesis through cancer associated fibroblast driven nutritional support and immunosuppression.
Cancer Discov. 2021 Feb;11(2)
:446-479. PMC ID:PMC7858242. |
|
Ward WH,
Meeker CR,
Handorf E,
Hill MV,
Einarson M,
Alpaugh RK,
Holden TL,
Astsaturov I,
Denlinger CS,
Hall MJ,
Reddy SS,
Sigurdson ER,
Dotan E,
Zibelman M,
Meyer JE,
Farma JM,
Vijayvergia N. Feasibility of Fitness Tracker Usage to Assess Activity Level and Toxicities in Patients With Colorectal Cancer.
JCO Clin Cancer Inform. 2021 Jan;5
:125-133. |
|
Dotan E,
Cardin DB,
Lenz HJ,
Messersmith WA,
O'Neil BH,
Cohen SJ,
Denlinger CS,
Shahda S,
Astsaturov I,
Kapoun AM,
Brachmann R,
Uttamsingh S,
Stagg R,
Weekes C. Phase 1b study of Wnt inhibitor ipafricept (IPA) with gemcitabine and nab-paclitaxel in patients with previously untreated stage IV pancreatic cancer (mPDAC).
Clin Cancer Res. 2020 Oct 15;26(20)
:5348-5357. PMC ID:PMC7572624. |
|
Gabitova-Cornell L,
Surumbayeva A,
Peri S,
Franco-Barraza J,
Restifo D,
Weitz N,
Ogier C,
Goldman AR,
Hartman TR,
Francescone R,
Tan Y,
Nicolas E,
Shah N,
Handorf EA,
Cai KQ,
O'Reilly AM,
Sloma I,
Chiaverelli R,
Moffitt RA,
Khazak V,
Fang CY,
Golemis EA,
Cukierman E,
Astsaturov I. Cholesterol Pathway Inhibition Induces TGF-β Signaling to Promote Basal Differentiation in Pancreatic Cancer.
Cancer Cell. 2020 Sep 15;38(4)
:567-583 e11. PMC ID:PMC7572882. |
|
Sahai E,
Astsaturov I,
Cukierman E,
DeNardo DG,
Egeblad M,
Evans RM,
Fearon D,
Greten FR,
Hingorani SR,
Hunter T,
Hynes RO,
Jain RK,
Janowitz T,
Jorgensen C,
Kimmelman AC,
Kolonin MG,
Maki RG,
Powers RS,
Puré E,
Ramirez DC,
Scherz-Shouval R,
Sherman MH,
Stewart S,
Tlsty TD,
Tuveson DA,
Watt FM,
Weaver V,
Weeraratna AT,
Werb Z. A framework for advancing our understanding of cancer-associated fibroblasts.
Nat Rev Cancer. 2020 Mar;20(3)
:174-186. PMC ID:PMC7046529. |
|
Gordon RE,
Zhang L,
Peri S,
Kuo YM,
Du F,
Egleston BL,
Ng JMY,
Andrews AJ,
Astsaturov I,
Curran T,
Yang ZJ. Statins Synergize with Hedgehog Pathway Inhibitors for Treatment of Medulloblastoma.
Clin Cancer Res. 2018 Mar 15;24(6)
:1375-1388. PMC ID:PMC5856627. |
|
Ang C,
Shields A,
Xiu J,
Gatalica Z,
Reddy S,
Salem ME,
Farhangfar C,
Hwang J,
Astsaturov I,
Marshall JL. Molecular characteristics of hepatocellular carcinomas from different age groups.
Oncotarget. 2017 Nov 24;8(60)
:101591-101598. PMC ID:PMC5731898. |
|
Lev A,
Lulla AR,
Wagner J,
Ralff MD,
Kiehl JB,
Zhou Y,
Benes CH,
Prabhu VV,
Oster W,
Astsaturov I,
Dicker DT,
El-Deiry WS. Anti-pancreatic cancer activity of ONC212 involves the unfolded protein response (UPR) and is reduced by IGF1-R and GRP78/BIP.
Oncotarget. 2017 Oct;8(47)
:81776-81793. PMC ID:PMC5669847. |
|
Astsaturov I. Future Clinical Trials. Genetically Driven Trials.
Surgical Oncology Clinics of North America. 2017 Oct;26(4)
:791-797. PMC ID:PMC5645064. |
|
Boland PM,
Meyer JE,
Berger AC,
Cohen SJ,
Neuman T,
Cooper HS,
Olszanski AJ,
Davey M,
Cheng JD,
Lebenthal A,
Burtness BA,
Scott WJ,
Astsaturov IA. Induction Therapy for Locally Advanced, Resectable Esophagogastric Cancer: A Phase I Trial of Vandetanib (ZD6474), Paclitaxel, Carboplatin, 5-Fluorouracil, and Radiotherapy Followed by Resection.
Am J Clin Oncol. 2017 Aug;40(4)
:393-398. PMC ID:PMC5026539. |
|
Gerson JN,
Skariah S,
Denlinger CS,
Astsaturov I. Perspectives of HER2-targeting in gastric and esophageal cancer.
Expert Opin Investig Drugs. 2017 May;26(5)
:531-540. PMC ID:PMC5563845. |
|
Naito S,
Makhov P,
Astsaturov I,
Golovine K,
Tulin A,
Kutikov A,
Uzzo RG,
Kolenko VM. LDL cholesterol counteracts the antitumour effect of tyrosine kinase inhibitors against renal cell carcinoma.
Br J Cancer. 2017 Apr 25;116(9)
:1203-1207. PMC ID:PMC5418451. |
|
Bobrov E,
Skobeleva N,
Restifo D,
Beglyarova N,
Cai KQ,
Handorf E,
Campbell K,
Proia DA,
Khazak V,
Golemis EA,
Astsaturov I. Targeted delivery of chemotherapy using HSP90 inhibitor drug conjugates is highly active against pancreatic cancer models.
Oncotarget. 2017 Jan 17;8(3)
:4399-4409. PMC ID:PMC5354841. |
|
Beglyarova N,
Banina E,
Zhou Y,
Mukhamadeeva R,
Andrianov G,
Bobrov E,
Lysenko E,
Skobeleva N,
Gabitova L,
Restifo D,
Pressman M,
Serebriiskii IG,
Hoffman JP,
Paz K,
Behrens D,
Khazak V,
Jablonski SA,
Weiner LM,
Golemis EA,
Astsaturov I. Screening of conditionally reprogrammed patient-derived carcinoma cells identifies ERCC3-MYC interactions as a target in pancreatic cancer.
Clin Cancer Res. 2016 Dec 15;22(24)
:6153-6163. PMC ID:PMC5161635. |
|
Beck TN,
Georgopoulos R,
Shagisultanova EI,
Sarcu D,
Handorf EA,
Dubyk C,
Lango MN,
Ridge JA,
Astsaturov I,
Serebriiskii IG,
Burtness BA,
Mehra R,
Golemis EA. EGFR and RB1 as Dual Biomarkers in HPV-negative Head and Neck Cancer.
Mol Cancer Ther. 2016 Oct;15(10)
:2486-2497. PMC ID:PMC5522587. |
|
Dotan E,
Alpaugh RK,
Ruth K,
Negin BP,
Denlinger CS,
Hall MJ,
Astsaturov I,
McAleer C,
Halbherr T,
Fittipaldi P,
Thrash-Bingham C,
Meropol NJ,
Cohen SJ. Prognostic Significance of MUC-1 in Circulating Tumor Cells in Patients With Metastatic Pancreatic Adenocarcinoma.
Pancreas. 2016
Sep;45(8)
:1131-5. PMC ID:PMC4983223. |
|
Vijayvergia N,
Boland PM,
Handorf E,
Gustafson KS,
Gong Y,
Cooper HS,
Sheriff F,
Astsaturov I,
Cohen SJ,
Engstrom PF. Molecular profiling of neuroendocrine malignancies to identify prognostic and therapeutic markers: a Fox Chase Cancer Center Pilot Study.
Br J Cancer. 2016 Aug 23;115(5)
:564-70. PMC ID:PMC4997552. |
|
Astsaturov I. The right and wrong of DOKing the nuclear receptor.
EBioMedicine. 2016 Jun;8
:7. PMC ID:PMC4919501. |
|
Boland PM,
Meyer JE,
Berger AC,
Cohen SJ,
Neuman T,
Cooper HS,
Olszanski AJ,
Davey M,
Cheng JD,
Lebenthal A,
Burtness BA,
Scott WJ,
Astsaturov IA. Induction Therapy for Locally Advanced, Resectable Esophagogastric Cancer: A Phase I Trial of Vandetanib (ZD6474), Paclitaxel, Carboplatin, 5-Fluorouracil, and Radiotherapy Followed by Resection.
Am J Clin Oncol. 2016 Mar 16
. PMC ID:PMC5026539. |
|
Proia DA,
Smith DL,
Zhang J,
Jimenez JP,
Sang J,
Ogawa LS,
Sequeira M,
Acquaviva J,
He S,
Zhang C,
Khazak V,
Astsaturov I,
Inoue T,
Tatsuta N,
Osman S,
Bates RC,
Chimmanamada D,
Ying W. HSP90 Inhibitor-SN-38 Conjugate Strategy for Targeted Delivery of Topoisomerase I Inhibitor to Tumors.
Mol Cancer Ther. 2015 Nov;14(11)
:2422-32. |
|
Gabitova L,
Restifo D,
Gorin A,
Manocha K,
Handorf E,
Yang DH,
Cai KQ,
Klein-Szanto AJ,
Cunningham D,
Kratz LE,
Herman GE,
Golemis EA,
Astsaturov I. Endogenous Sterol Metabolites Regulate Growth of EGFR/KRAS-Dependent Tumors via LXR.
Cell Rep. 2015 Sep 22;12(11)
:1927-38. PMC ID:PMC4581991. |
|
Shaikh T,
Ruth K,
Scott WJ,
Burtness BA,
Cohen SJ,
Konski AA,
Cooper HS,
Astsaturov I,
Meyer JE. Increased time from neoadjuvant chemoradiation to surgery is associated with higher pathologic complete response rates in esophageal cancer.
Ann Thorac Surg. 2015 Jan;99(1)
:270-6. PMC ID:PMC4284823. |
|
Cohen SJ,
Konski AA,
Putnam S,
Ball DS,
Meyer JE,
Yu JQ,
Astsaturov I,
Marlow C,
Dickens A,
Cade DN,
Meropol NJ. Phase I study of capecitabine combined with radioembolization using yttrium-90 resin microspheres (SIR-Spheres) in patients with advanced cancer.
Br J Cancer. 2014 Jul 15;111(2)
:265-71. |
|
Beeharry N,
Banina E,
Hittle J,
Skobeleva N,
Khazak V,
Deacon S,
Andrake M,
Egleston BL,
Peterson JR,
Astsaturov I,
Yen TJ. Re-purposing clinical kinase inhibitors to enhance chemosensitivity by overriding checkpoints.
Cell Cycle. 2014 Jul;13(14)
:2172-91. PMC ID:PMC4111673. |
|
Perkins J,
Boland P,
Cohen SJ,
Olszanski AJ,
Zhou Y,
Engstrom P,
Astsaturov I. Successful Imatinib Therapy for Neuroendocrine Carcinoma With Activating KIT Mutation: A Case Study.
J Natl Compr Canc Netw. 2014 Jun;12(6)
:847-52. PMC ID:PMC4112647. |
|
Gabitova L,
Gorin A,
Astsaturov I. Molecular pathways: sterols and receptor signaling in cancer.
Clin Cancer Res. 2014 Jan 1;20(1)
:28-34. PMC ID:PMC3859141. |
|
Mehra R,
Serebriiskii IG,
Burtness B,
Astsaturov I,
Golemis EA. Aurora kinases in head and neck cancer.
Lancet Oncology. 2013 Sep;14(10)
:E425-E435. |
|
Liu HQ,
Xiao F,
Serebriiskii IG,
O'Brien SW,
Maglaty MA,
Astsaturov I,
Litwin S,
Martin LP,
Proia DA,
Golemis EA,
Connolly DC. Network Analysis Identifies an HSP90-Central Hub Susceptible in Ovarian Cancer.
Clinical Cancer Research. 2013 Sep;19(18)
:5053-5067. PMC ID:PMC 3778161. |
|
Bagnyukova TV,
Restifo D,
Beeharry N,
Gabitova L,
Li T,
Serebriiskii IG,
Golemis EA,
Astsaturov I. DUSP6 regulates drug sensitivity by modulating DNA damage response.
British Journal of Cancer. 2013 Aug;109(4)
:1063-1071. PMC ID:PMC 3749559. |
|
Nikonova AS,
Astsaturov I,
Serebriiskii IG,
Dunbrack RL,
Golemis EA. Aurora A kinase (AURKA) in normal and pathological cell division.
Cellular and Molecular Life Sciences. 2013 Feb;70(4)
:661-687. PMC ID:PMC3607959. |
|
Paltser G,
Liu XJ,
Yantha J,
Winer S,
Tsui H,
Wu P,
Maezawa Y,
Cahill LS,
Laliberte CL,
Ramagopalan SV,
DeLuca GC,
Sadovnick AD,
Astsaturov I,
Ebers GC,
Henkelman RM,
Salter MW,
Dosch HM. TRPV1 Gates Tissue Access and Sustains Pathogenicity in Autoimmune Encephalitis.
Molecular Medicine. 2013 Jan-Jun;19
:149-159. PMC ID:PMC3745593. |
|
Sukhanova A,
Gorin A,
Serebriiskii IG,
Gabitova L,
Zheng H,
Restifo D,
Egleston BL,
Cunningham D,
Bagnyukova T,
Liu H,
Nikonova A,
Adams GP,
Zhou Y,
Yang DH,
Mehra R,
Burtness B,
Cai KQ,
Klein-Szanto A,
Kratz LE,
Kelley RI,
Weiner LM,
Herman GE,
Golemis EA,
Astsaturov I. Targeting C4-demethylating genes in the cholesterol pathway sensitizes cancer cells to EGF receptor inhibitors via increased EGF receptor degradation.
Cancer Discov. 2013 Jan;3(1)
:96-111. PMC ID:PMC3546138. |
|
Gorin A,
Gabitova L,
Astsaturov I. Regulation of cholesterol biosynthesis and cancer signaling.
Current Opinion in Pharmacology. 2012 Dec;12(6)
:710-716. PMC ID:PMC 3504641. |
|
Dotan E,
Meropol NJ,
Zhu F,
Zambito F,
Bove B,
Cai KQ,
Godwin AK,
Golemis EA,
Astsaturov I,
Cohen SJ. Relationship of increased aurora kinase A gene copy number, prognosis and response to chemotherapy in patients with metastatic colorectal cancer.
British Journal of Cancer. 2012 Feb;106(4)
:748-755. PMC ID:PMC3322945. |
|
Wang SZ,
Astsaturov IA,
Bingham CA,
McCarthy KM,
von Mehren M,
Xu W,
Alpaugh RK,
Tang Y,
Littlefield BA,
Hawkins LD,
Ishizaka ST,
Weiner LM. Effective antibody therapy induces host-protective antitumor immunity that is augmented by TLR4 agonist treatment.
Cancer Immunology Immunotherapy. 2012 Jan;61(1)
:49-61. PMC ID:PMC3517883. |
|
Chun YS,
Cooper HS,
Cohen SJ,
Konski A,
Burtness B,
Denlinger CS,
Astsaturov I,
Hall MJ,
Hoffman JP. Significance of Pathologic Response to Preoperative Therapy in Pancreatic Cancer.
Annals of Surgical Oncology. 2011 Dec;18(13)
:3601-3607. |
|
Astsaturov IA,
Meropol NJ,
Alpaugh RK,
Burtness BA,
Cheng JD,
McLaughlin S,
Rogatko A,
Xu ZH,
Watson JC,
Weiner LM,
Cohen SJ. Phase II and Coagulation Cascade Biomarker Study of Bevacizumab With or Without Docetaxel in Patients With Previously Treated Metastatic Pancreatic Adenocarcinoma.
American Journal of Clinical Oncology-Cancer Clinical Trials. 2011 Feb;34(1)
:70-75. PMC ID:PMC3030655. |
|
Bagnyukova T,
Serebriiskii IG,
Zhou Y,
Hopper-Borge EA,
Golemis EA,
Astsaturov I. Chemotherapy and signaling: How can targeted therapies supercharge cytotoxic agents?.
Cancer Biol Ther. 2010 Nov 2;10(9)
:839-853. |
|
Chun YS,
Milestone BN,
Watson JC,
Cohen SJ,
Burtness B,
Engstrom PF,
Haluszka O,
Tokar JL,
Hall MJ,
Denlinger CS,
Astsaturov I,
Hoffman JP. Defining Venous Involvement in Borderline Resectable Pancreatic Cancer.
Annals of Surgical Oncology. 2010 Nov;17(11)
:2832-2838. |
|
Astsaturov I,
Ratushny V,
Sukhanova A,
Einarson MB,
Bagnyukova T,
Zhou Y,
Devarajan K,
Silverman JS,
Tikhmyanova N,
Skobeleva N,
Pecherskaya A,
Nasto RE,
Sharma C,
Jablonski SA,
Serebriiskii IG,
Weiner LM,
Golemis EA. Synthetic lethal screen of an EGFR-centered network to improve targeted therapies.
Sci Signal. 2010 ;3(140)
:ra67. PMC ID:PMC2950064. |
|
Ratushny V,
Astsaturov I,
Burtness BA,
Golemis EA,
Silverman JS. Targeting EGFR resistance networks in head and neck cancer.
Cell Signal. 2009 Aug;21(8)
:1255-68. PMC ID:PMC2770888. |
|
Hopper-Borge EA,
Nasto RE,
Ratushny V,
Weiner LM,
Golemis EA,
Astsaturov I. Mechanisms of tumor resistance to EGFR-targeted therapies.
Expert Opinion on Therapeutic Targets. 2009 Mar;13(3)
:339-362. PMC ID:PMC2670612. |
|
Panikkar RP,
Astsaturov I,
Langer CJ. The emerging role of cetuximab in head and neck cancer: a 2007 perspective.
Cancer Invest. 2008 Feb;26(1)
:96-103. |
|
Borghaei H,
Binyamin L,
Astsaturov I,
Weiner AM. Antibody therapy of cancer.
Molecular targeting in oncology. 2008
:371-. |
|
Astsaturov I,
Cohen RB,
Harari PM. Clinical application of EGFR inhibitors in head and neck squamous cell cancer.
Cancer Treat Res. 2008 ;139
:135-52. |
|
Burtness B,
Weiner L,
Astsaturov I,
Golemis E. Targeting Her: Can resistance to EGFR inhibitors be overcome?.
. 2008
:80-80. |
|
Khazak V,
Astsaturov I,
Serebriiskii IG,
Golemis EA. Selective Raf inhibition in cancer therapy.
Expert Opinion on Therapeutic Targets. 2007 Dec;11(12)
:1587-1609. |
|
Astsaturov I,
Cohen RB,
Harari P. EGFR-targeting monoclonal antibodies in head and neck cancer.
Curr Cancer Drug Targets. 2007 Nov;7(7)
:650-65. |
|
Astsaturov I,
Cohen R,
Harari P. Clinical application of EGFR inhibitors in head and neck squamous cell cancer.
Handbook of radiotherapy physics : theory and practice. 2007
:132-149. |
|
Astsaturov I,
Cohen RB,
Harari PM. EGFR-targeting monoclonal antibodies in head and neck cancer.
Current Cancer Drug Targets. 2006 Dec;6(8)
:691-710. |
|
Astsaturov I,
Cohen RB,
Harari P. Targeting epidermal growth factor receptor signaling in the treatment of head and neck cancer.
Expert Rev Anticancer Ther. 2006 Sep;6(9)
:1179-93. |
|
Faculty
Publications
